WO2006111745A3 - Composition and method for treating viral infection - Google Patents

Composition and method for treating viral infection Download PDF

Info

Publication number
WO2006111745A3
WO2006111745A3 PCT/GB2006/001432 GB2006001432W WO2006111745A3 WO 2006111745 A3 WO2006111745 A3 WO 2006111745A3 GB 2006001432 W GB2006001432 W GB 2006001432W WO 2006111745 A3 WO2006111745 A3 WO 2006111745A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
composition
viral infection
treating viral
amino acid
Prior art date
Application number
PCT/GB2006/001432
Other languages
French (fr)
Other versions
WO2006111745A2 (en
Inventor
Paula Barnard
Colin Robertson
Original Assignee
Viragen Inc
Paula Barnard
Colin Robertson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507963A external-priority patent/GB0507963D0/en
Priority claimed from GB0522732A external-priority patent/GB0522732D0/en
Application filed by Viragen Inc, Paula Barnard, Colin Robertson filed Critical Viragen Inc
Publication of WO2006111745A2 publication Critical patent/WO2006111745A2/en
Publication of WO2006111745A3 publication Critical patent/WO2006111745A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Abstract

Described is a novel polypeptide which has homology with human interferon alpha (14). The polypeptide, is characterised by the substitution of the amino acid residue at position (72) of the amino acid sequence so as to remove a residue which is capable of being glycosylated. The polypeptide of the invention may be produced by recombinant means in either a prokaryotic or eukaryotic production systems and is seem to mediate a potent anti-viral effect. Further provided is human interferon alpha (14) which is produced by recombinant means in systems other than a prokaryotic production system, said recombinantly derived alpha 14 being shown to have potent anti-viral activity.
PCT/GB2006/001432 2005-04-20 2006-04-20 Composition and method for treating viral infection WO2006111745A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0507963.7 2005-04-20
GB0507963A GB0507963D0 (en) 2005-04-20 2005-04-20 Composition and method for treating disease
GB0522732.7 2005-11-07
GB0522732A GB0522732D0 (en) 2005-11-07 2005-11-07 Composition and method for treating disease
US74173405P 2005-12-02 2005-12-02
US60/741.734 2005-12-02

Publications (2)

Publication Number Publication Date
WO2006111745A2 WO2006111745A2 (en) 2006-10-26
WO2006111745A3 true WO2006111745A3 (en) 2007-03-29

Family

ID=36968957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001432 WO2006111745A2 (en) 2005-04-20 2006-04-20 Composition and method for treating viral infection

Country Status (1)

Country Link
WO (1) WO2006111745A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619816D0 (en) * 2006-10-06 2006-11-15 Viragen Inc Novel interferon-alpha constructs for use in the treatment of cancer
GB201215873D0 (en) * 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
CN114917326A (en) * 2017-08-06 2022-08-19 复旦大学 Application of human alpha interferon subtype in preparing anti-hepatitis B virus medicine
KR20230020943A (en) * 2020-03-16 2023-02-13 아이엘씨 테라퓨틱스 리미티드 Hybrid interferons for the treatment of viral infections
GB202102261D0 (en) * 2021-02-17 2021-03-31 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
WO2022079205A1 (en) * 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005003157A2 (en) * 2003-06-10 2005-01-13 Xencor, Inc. Interferon variants with improved properties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005003157A2 (en) * 2003-06-10 2005-01-13 Xencor, Inc. Interferon variants with improved properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NYMAN TUULA A ET AL: "Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 329, no. 2, 15 January 1998 (1998-01-15), pages 295 - 302, XP002267159, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
WO2006111745A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2006111745A3 (en) Composition and method for treating viral infection
WO2005079315A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
IL187293A (en) Methods for producing n-linked glycosylated proteins and host prokaryotic organisms
WO2005009379A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2008025164A8 (en) Family 6 cellulases with increased thermostability, thermophilicity, and alkalophilicity
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
WO2007091030A3 (en) Peptide sequences and compositions
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
NZ592704A (en) Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
IL288541B (en) Vaccine against rsv
WO2007001361A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A3 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
NZ233974A (en) Peptide inhibitors of human leucocyte elastases, recombinant production and compositions
MY167485A (en) Recombinant human interferon-like proteins
NZ586430A (en) Mutant forms of streptolysin o (slo)
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
AU2002330289A1 (en) Preparation of a therapeutic composition
WO2006097432A3 (en) Keratin-binding desmoplakin polypeptide sequences
WO2008041014A3 (en) Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
WO2007058267A8 (en) Novel protein and gene encoding the protein
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
HK1131162A1 (en) Cytokine derivatives
WO2005056051A3 (en) Hepatitis b vaccines and compositions
WO2007101948A3 (en) Novel vaccines for treating or preventing infections by parasites of the family taenidae and in particular of the genus echinococcus
WO2022031733A3 (en) Keratinolytic polypeptides and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06726824

Country of ref document: EP

Kind code of ref document: A2